Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement
ACCESS Newswire (Mon, 3-Mar 7:34 AM ET)
ACCESS Newswire (Tue, 25-Feb 7:32 AM ET)
Aspire Biopharma Holdings, Inc. Sees Premarket Decline Following Securities Purchase Agreement
Market Chameleon (Fri, 21-Feb 3:29 AM ET)
Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement
ACCESS Newswire (Thu, 20-Feb 6:18 PM ET)
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tract.
Aspire Biopharma Hldgs trades on the NASDAQ stock market under the symbol ASBP.
As of March 10, 2025, ASBP stock price declined to $0.77 with 184,871 million shares trading.
ASBP has a market cap of $35.47 million. This is considered a Sub-Micro Cap stock.
ASBP support price is $.60 and resistance is $1.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ASBP shares will trade within this expected range on the day.